The Claim
In adults with metabolic dysfunction-associated steatotic liver disease (MASLD) without type 2 diabetes, 12 weeks of liraglutide therapy and matched lifestyle-induced weight loss both reduce liver fat content by approximately 7.5%, with no significant difference between the two interventions, indicating that weight loss itself is the primary driver of hepatic steatosis improvement.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with MASLD but without type 2 diabetes, 12 weeks of liraglutide treatment and lifestyle changes that produce the same amount of weight loss both reduce liver fat by about 7.5%, and the reduction is not greater with liraglutide than with weight loss alone.
See the scientific wording
In adults with metabolic dysfunction-associated steatotic liver disease (MASLD) without type 2 diabetes, 12 weeks of liraglutide therapy and matched lifestyle-induced weight loss both reduce liver fat content by approximately 7.5%, with no significant difference between the two interventions, indicating that weight loss itself is the primary driver of hepatic steatosis improvement.
When a person loses weight, fat cells release less fatty acid into the blood, the liver gets less fatty acid to store as fat, and the liver also makes less new fat from sugar, so liver fat goes down.
What the research says
1 studyIn people with fatty liver who don’t have diabetes, taking liraglutide or losing the same amount of weight by eating less both cut liver fat by about the same amount—so it’s the weight loss itself, not the medicine, that helps the liver.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.